MEDICA LABMED FORUM: Discussions on Hot Issues, Current Trends and Innovations in Lab Medicine
|
By LabMedica International staff writers Posted on 12 Sep 2023 |

This year, the MEDICA LABMED FORUM will once again be a part of the renowned international medical trade fair MEDICA (Düsseldorf, Germany) scheduled for 13-16 November 2023. The forum aims to cover a wide range of topics including cancer, heart diseases, infections, new anti-bacterial substances, and the role of digital technology and artificial intelligence (AI) in medicine. Over the years, the forum has gained significant attention as an integral part of the trade fair. Despite the complexity of the subjects for discussion, all presentations have been designed to be concise, clear, and understandable, and can be continued further in panel discussions.
The inaugural day of MEDICA will dive into two particularly controversial subjects that are stirring up the laboratory medicine community: the "In-Vitro Diagnostics Regulation" (IVDR) and its implications for smaller IVD companies and specialized labs, as well as the growing role of AI with its potential and pitfalls. There will be an in-depth discussion on how to navigate the challenges brought about by new EU guidelines for diagnostic test quality assurance. This will be followed by an engaging discussion on how AI technologies, such as machine learning, are poised to transform lab work, particularly in automating the evaluation of microscopic images and complex data, like those used in leukemia diagnosis.
The second day will focus on a discussion of groundbreaking advancements in the fields of oncology and cardiology. Recent research has highlighted the powerful diagnostic capabilities of blood tests in cancer treatment and management. Circulating tumor cells and nucleic acids, for example, are emerging as secondary but vital methods, providing new angles beyond traditional tissue examinations in oncology. Meanwhile, molecular diagnostic tests are reshaping cardiology, offering enhanced risk assessments for arteriosclerotic cardiovascular diseases. Additionally, genetic tests are gaining significance in the treatment of congenital heart defects, and new concepts like thromboinflammation are coming into play.
The third day of the Forum is traditionally allocated to the next scientific generation in the field of laboratory medicine. Every year, young participants are invited to report on their current research and give an outlook on the future of the scientific field. The leitmotif for 2023 is “data sciences," which captivates young minds, particularly due to the intelligent analysis of huge lab data sets. Presentation subjects will range from AI-enabled image evaluations to the analysis of complex lab data and automated generation of diagnostic reports. The discussions will also include the subject of practical applications in healthcare settings and the diagnostics industry.
The final day of the MEDICA LABMED FORUM will kick off with an overview of diagnostic techniques that significantly cut down the time required to detect pathogens, thus allowing timely and effective treatment strategies. There will be a special focus on the rapid identification of the bacteria causing sepsis and targeted antibiotic usage. Moving beyond traditional antibiotic treatments, innovative ways to combat resistance will be explored. This includes discussions on alternative approaches like using small molecules against bacterial toxins or exploring phage therapy.
To wrap up the event, there will be a deep dive into “Next Generation Sequencing” (NGS) and bioinformatics, with a spotlight on characterizing the microbiomes of newborns, a notably vulnerable patient group. Another traditional feature of MEDICA is the forward-looking presentations related to future trends in diagnostics and life sciences, with a special focus this year on infectious diseases and antibiotic resistance, recognized as an escalating health crisis. The forum has steadily grown over the years, with last year's MEDICA and its parallel event COMPAMED drawing a crowd of 81,000 professionals, 75% of whom were from international backgrounds.
Related Links:
MEDICA
Latest Industry News
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
- Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio
- Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders
- Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more







